Healthy human prostate epithelial cells have the unique ability to produce and secrete large amounts of citrate into the lumen of the prostate. Citrate is a Krebs cycle metabolite produced in the condensation reaction between acetyl-CoA and oxaloacetate in the mitochondria of the cell. Using 13 C enriched substrates, the contributions of different metabolic pathways to this production and secretion of citrate could be identified. In this work we present a probabilistic model describing the production and secretion of citrate in the mitochondria of prostatic epithelial cells. We derived equations for the secretion probability of citrate and the contribution of pyruvate dehydrogenase complex (PDC) versus the anaplerotic pyruvate carboxylase (PC) pathways in supplying the Krebs cycle with carbons from pyruvate for the production of citrate. This measure is independent of initial 13 C-enrichment of the administered supplements and of 13 C J-coupling patterns, making this method robust also if SNR is low. We propose that these equations can be used to distinguish between citrate metabolism in healthy prostate tissue cells and in malignant cells, or they can be used to follow changes in citrate metabolism during the process towards malignancy.
Introduction
Healthy prostate epithelial cells have the unique capability of secreting citrate in the ducts or lumen of the prostate. 1 , where it can reach levels up to about 180 mM. Citrate accumulation in the prostate is promoted by inhibition of the citrate converting enzyme m-aconitase through zinc binding, which is taken up at relatively high levels in epithelial prostate cells. [1] [2] [3] The characteristic citrate accumulation is lost upon malignancy, 4 and a decreased citrate signal in MR spectroscopic images of the prostate is used as a biomarker for the presence of cancer. [5] [6] [7] Prostate cancer accounts for one in five cancers and is responsible for one in ten cancer related deaths in men worldwide. 8, 9 Understanding metabolic reprogramming in malignant transformation may help to better diagnose and treat prostate cancer. [10] [11] [12] [13] Citrate is the product of a condensation reaction of oxaloacetate and acetyl-CoA catalyzed by citrate synthase as the first step of the Krebs cycle. A major compound from which acetyl-CoA is derived is glucose, which is metabolized into pyruvate by glycolysis and subsequently enters the the mitochondria where it is converted into acetyl-CoA to enter the Krebs cycle. In this step two carbons enter the cycle, which is equal to the carbon efflux as carbon dioxide, during one Krebs cycle turn. Because of citrate efflux into the luminal space, removing six carbons from the cycle, anaplerotic contributions are required to maintain the carbon pool of the Krebs cycle. One of these anaplerotic contributions can come from pyruvate being converted into oxaloacetate by pyruvate carboxylase (PC). The influx of this four-carbon metabolite can partly balance the efflux of six carbon citrate every Krebs cycle turn.
The carbon flow for citrate production and secretion can be assessed by supplying prostate tissue or cells in vivo or in vitro with 13 C substrates and monitoring the fate of the 13 C-labels by 13 C MR spectroscopy or high resolution 13 C NMR spectroscopy and looking at the specific 13 C labeling of metabolic products. In this way metabolic synthesis routes can be delineated and quantified.
Multiple metabolic flux modeling studies have modeled Krebs cycle activity in different tissues and cell types under different conditions in literature. This is done using (extensive) metabolic networks involving fluxes between the metabolites in the network, like positional isotopomers 14 , bonded cumomer analysis 15 or elementary metabolite unit based methods 16 . For example, in human melanoma cell line DB1, rat C6 glioma cells, H460 NSCLC cells, hepatocytes and brown adipocytes and in isolated cardiac mitochondria relative fluxes of total TCA cycle activity V T CA and exchange flux V x of α-ketoglutarate with glutamate V x are determined in vitro. [17] [18] [19] [20] [21] [22] [23] But also in vivo in mouse and rat brain and heart [24] [25] [26] [27] [28] and human brain. [29] [30] [31] Overall, the different contributions of pyruvate carboxylase activity, malic enzyme activity, glutaminolysis and other cataplerotic and anaplerotic processes 32 for different tissues and cells make it hard to generalize Krebs cycle metabolism in such a way that it can be used to predict prostate metabolism. The fast exchange between glutamate and α-ketoglutarate is one common element in these studies. In prostate no such studies have been performed to date except for hyperpolarization studies measuring (semi)quantitative fluxes in prostate. 33 The unique citrate metabolism of the prostate makes it hard to translate values found in these other studies to prostate metabolism.
The unique characteristic secretion of citrate by prostatic cells provides a six-carbon readout of this Krebs cycle activity not used before as far as we know. A first practical approach to explore this property would be in studies of prostate cells, but most prostatic epithelial cell lines lack the capacity of citrate secretion. However, the prostate cancer metastasis cell line LNCaP has been shown to have the capacity to secrete citrate and therefore can serve as a convenient model system to evaluate if 13 C labeling of secreted citrate can be explored as a readout for carbon flow inside the cell. [34] [35] [36] Using only simple ratios that can be extracted from MR spectroscopic data or high resolution 13 C NMR spectra we developed a simple probabilistic model for cellular citrate production in this work. On one hand we determine an index for citrate production and secretion versus Krebs cycle consumption and on the other hand an estimate of the balance between pyvuvate carboxylase (PC) and pyruvate dehydrogenase complex (PDC) activity in citrate production.
Data collection
To follow citrate metabolism in healthy or malignant prostate epithelial tissue in vivo, or in vitro in primary cell cultures or cell lines, [ 
Quantitative model
The distribution of 13 C carbons in citrate, as determined from NMR spectra, reflects on the ratio of pyruvate going into the Krebs cycle via pyruvate carboxylase (as oxaloacetate) and pyruvate dehydrogenase (as acetyl-CoA) on one hand and on the fraction of molecules leaving the Krebs cycle every turn to be secreted into the lumen or incubation medium on the other hand. Here we derive a probabilistic model describing prostatic citrate production depending on a (constant) secretion probability c and on the fractions of carbons entering via acetyl-CoA (f P DC ) or oxaloacetate (f P C ), with f P C + f P DC = 1. The 13 C labeling at the six different positions in citrate secreted and carbon dioxide produced at cycle turn n is described by − → C (n).
Since every Krebs cycle turn a fraction c of citrate leaves the cycle and fraction (1 − c) remains in the cycle a factor c(1 − c) n is included. For example, if at n = 3 citrate molecules are secreted with 20% label on C 2 , 10% on C 4 and 5% on C 5 and C 6 , and 3% label is lost in carbon dioxide, this would be:
Equations for this are derived further on in this paper.
Fate of
13 C labels in the Krebs cycle
When a 13 C label enters the Krebs cycle it can end up at different positions in citrate (see Figure  1 ). If a label continues down the Krebs cycle it can eventually end up in citrate again, but now at a different position, or even distributed equally over two citrate carbon positions. This is because succinate and fumarate are symmetrical intermediates in the Krebs cycle resulting in indistinguishable labelings of C1 and C4 or C2 and C3 in succinate and fumarate. Eventually this leads to an equal distribution of 13 C labels at two carbon positions in citrate. The position of 13 C labels at citrate carbons C1-C6 and oxaloacetate (OAA) at cycle turn n + 1 versus n are shown in Table 1 . First labeling of citrate (n = 0)
The ( 13 C) carbons of pyruvate can enter the Krebs cycle via the pyruvate carboxylase (PC) and the pyruvate dehydrogenase complex (PDC) route. We define Krebs cycle turn n as the number of full Krebs cycle turns completed before secretion of citrate from the Krebs cycle. This means that if citrate is secreted right after it is labeled, this is Krebs cycle turn n = 0. This is the only cycle turn where 13 C carbons enter the Krebs cycle via PC because the oxaloacetate during the next Krebs cycle turns (n > 0) originates from the citrate in the previous Krebs cycle turn Figure 2 .
13 C labeled oxaloacetate (OAA) and 13 C labeled acetyl-CoA are formed and can together with unlabeled oxaloacetate or acetyl-CoA undergo a condensation reaction to produce unlabeled, single-or double 13 C labeled citrate. Resulting in citrate labeled at C2 (PDC) and/or C4 (PC) respectively at n = 0. If [2,5- 13 C 2 ]glucose or [2-13 C]pyruvate is used as substrate the scheme in Figure 3 can be produced. Resulting in citrate labeling at C1 (PDC) and/or C3 (PC) respectively at n = 0. Note here that if P and A were to be fractions of 13 C label ending up in oxaloacetate via PC or acetyl-CoA via PDC respectively, the resulting distribution of 13 C label over the two citrate positions that are possibily labeled at n = 0 is equal to P at one position and A at the other. For the [ 
Pyruvate carboxylase vs pyruvate dehydrogenase complex
To determine the fractional contributions of the PC and PDC routes to the final citrate pool in the luminal fluid or incubation medium it is essential to realize that depending on how many Krebs cycle turns a 13 C label completes before being secreted, the contribution is different. Let's start with fraction A 13 C labels getting into citrate via PDC and fraction P 13 C labels getting into citrate via PC. Subsequently fraction c of the citrate will be secreted (we define this as Krebs cycle turn n = 0) and fraction (1 − c) continues in the Krebs cycle. Now (1 − c) carbon skeletons will be labeled again upon condensation of the carbon skeleton (oxaloacetate) with (1 − c)
13 C acetyl-CoA forming (1−c) citrate. Of this citrate again fraction c is secreted (n = 1) and fraction (1 − c) continues down the Krebs cycle and the process repeats itself. This is summarized in Figure 5 . Pyruvate carboxylase only contributes to the 13 C labeling of the citrate pool in the luminal fluid or incubation medium at n = 0 and pyruvate dehydrogenase complex contributes to the citrate pool during all Krebs cycle turns. In general, during cycle turn n > 0 there will be A(1 − c) n labels entering the cycle and Ac(1 − c) n citrate molecules will be secreted. Only at n = 0 there will be A + P labels entering the cycle and c(A + P ) citrate molecules will be secreted. The sum of all fractions of 13 C labels entering the Krebs cycle has to be equal to f P C + f P DC = 1 and since the only time labels originating from the PC route can enter the cycle is at turn n = 0, we can easily see fraction f P C is equal to the fraction P described above. Fraction f P DC has to be equal to the sum of fractions of 13 C labels entering via acetyl-CoA, which comes down to the following sum:
This means that if at n = 0 fraction f P C of pyruvate 13 C labels enter the cycle via the PC route and fraction A = cf P DC enters the cycle via the PDC route, summed over all possible Krebs cycle turns a total of f P C + cf P DC c = f P C + f P DC = 1 13 C labels enter the Krebs cycle ( Figure  4 ). Figure 4 : Fractions pyruvate carboxylase f P C and pyruvate dehydrogenase complex f P DC versus secretion probability c. The sum of f P C and f P DC is equal to 1. The initial fraction (at n = 0) of carbon entering the Krebs cycle via PDC depends on the value of c, since
≤ f P C , since for every oxaloacetate labeled via the PC route, there is an acetyl-CoA needed (labeled by PDC) at n = 0, making the blue line start at PC=cPDC. 
C-Pyr
A(1 − c) ∞ acetyl-CoA n = ∞ etc A(1 − c) 2 13 C acetyl-CoA n = 2 A(1 − c) 13 C acetyl-CoA n = 1 A 13 C acetyl-CoA n = 0 P 13 C oxaloacetate n = 0 f P DC f P C = P + A n=∞ n=0 (1 − c) n = P + A c = 1 ⇒ f P C = P f P DC = A c
Average number of completed Krebs cycle turns before citrate secretion
The average number of Krebs cycle turns before secretion of citrate (This is not the same as the average number of Krebs cycle turns a 13 C carbon completes, see Appendices for the average number of cycle turns a 13 C carbon completes) depends on the secretion probability c. To calculate this average number of cycle turns < n > the sum can be calculated of the fractions secreted every cycle c(1 − c) n multiplied with their corresponding Krebs cycle turn indices n.
The average number of cycle turns is equal to the ratio of the fraction of molecules that stay in the Krebs cycle (1 − c) over the fraction of molecules that are secreted c.
Effect of 13 C enrichment
We assume that the pool of 13 C pyruvate, present during the infusion or incubation period, is much larger than the Krebs cycle pool of 13 C carbons. So we assume the enrichment of this pool to be constant as well. Until now we assumed all pyruvate or glucose to be 13 C labeled. This probably doesn't reflect the true situation so introducing a enrichment factor in the equations could correct for this. Suppose only fraction of pyruvate is 13 C labeled, then fractions cf
(via pyruvate dehydrogenase complex) and f P C (via pyruvate carboxylase) of 13 C carbons will enter the Krebs cycle at n = 0, cf P DC (1 − c) at n = 1, cf P DC (1 − c) 2 at n = 2 and so forth.
This means the contributions of the individual cycle turns to the sum (final 13 C distribution) are all multiplied by and we can assume a constant enrichment factor of = 1 when deriving equations for the 13 [1,6- 13 C 2 ]glucose the 13 C label will be located at the C3 position of pyruvate as shown in section "First labeling of citrate (n = 0)". Subsequently this label can end up at the oxaloacetate C3 position or acetyl-CoA C2 position. The first will result in labeling at C2 of citrate, the latter at C4. So, the 13 C carbon distribution in citrate at cycle turn n = 0 will look like (neglecting carbon dioxide for now):
After one turn the distribution will have shifted according to Table 1 and more label is added at the C2 position via PDC.
We assume here that all the label being added at C2 is 13 C labeled. We discussed this assumption in section "Effect of 13 C enrichment". For cycle turns n ≥ 2 the distribution at cycle n can be written in a more general way as:
We would like to know the distribution of 13 C labels over the six citrate carbons in the extracellular fluid or incubation medium when the citrate 13 C distribution is in a steady state. This can be calculated by summing the contributions of citrate secreted during each individual Krebs cycle turn n to the total secreted citrate:
These equations give the 13 C label distribution over the six carbons in secreted citrate. This distribution only depends on secretion probability c and the fraction of carbon entering the Krebs cycle via the pyruvate carboxylase route, f P C , since
2 is plotted against c in figure 6. 13 C label enters the Krebs cycle, it can end up at the oxaloacetate C2 position, via pyruvate carboxylase, or at the acetyl-CoA C1 position via pyruvate dehydrogenase complex. The first will result in a first labeling at C3 of citrate, the latter at C1. So, the 13 C carbon distribution in citrate at cycle turn n = 0 will look like (again, neglecting carbon dioxide for now):
After one turn this distribution will have shifted again like in section "Providing [1,6-13 C 2 ]glucose or [3- 13 C]pyruvate to tissue/cells" (see also Table 1 ) and new label is added at the C1 (via PDC) position of citrate every cycle turn.
From cycle turn n ≥ 2 on the distribution at cycle turn n can be written in a more general way as
The distribution of 13 C carbons over the carbons in the secreted citrate can be calculated again by calculating the sum of the contributions of all individual Krebs cycle turns n
These equations give the steady state 13 C label distribution in citrate in the extracellular space or incubation medium after supplementation with [2,5-
The distribution depends on secretion probability c and on the fractions of 13 C carbon entering the Krebs cycle via the pyruvate carboxylase route, f P C and pyruvate dehydrogenase complex f P DC (with f P DC = 1 − f P C ). The distribution of 13 C carbons for f P C = 0.2) is shown in Figure 7 plotted against secretion probability c.
CO 2 production
Next to citrate production and secretion we also have to take into account how much carbon dioxide is produced every cycle and sum these contributions to see how much 13 C labels are lost as carbon dioxide. During a Krebs cycle turn one six-carbon molecule of citrate is converted into a four-carbon metabolite oxaloacetate and two carbons are lost as carbon dioxide. The first carbon is lost during the conversion of isocitrate into α-ketoglutarate and the second carbon is lost in the next step of the Krebs cycle during the conversion of α-ketoglutarate into succinylCoA. The first originates from the C6 carbon in citrate and the latter originates from citrate C5. So, the carbon dioxide production at cycle turn n is equal to the sum of citrate carbons C5 and C6 at this cycle turn n times (1 − c) instead of times c since the production of carbon dioxide during cycle n takes place after the secretion of (1 − c) n citrate. In other words, only the 13 C carbons at C5 and C6, which are not secreted (fraction (1 − c) n ) at cycle n, are lost as carbon dioxide. This means we could calculate the carbon dioxide production at cycle turn n by adding the 13 C distribution at C5 and C6 and multiply this by 1−c c . Because the 13 C distribution at C5 and C6 is equal, this could be written as:
Figure 7:
13 C distribution over the six citrate carbons versus secretion probability c after providing [ To calculate the resulting CO 2 produced over time the contributions of all cycle turns have to be summed.
Another way of calculating this is by evaluating the individual contributions for every cycle turn −−→ CO 2 (n) to the total CO 2 for different values of n, like we did before for the carbons in citrate. 
This means we can calculate the total amount of CO 2 by summing these contributions:
In the last step the equation has been rewritten to show that the total CO 2 indeed is equal to the final 13 C distribution at citrate C5 (or C6) times 2 1−c c . Since the total 13 C entering the Krebs cycle in our model is equal to f P C + f P DC = 1 and we only take citrate production/secretion and CO 2 into account in our model the total 13 C found in citrate and CO 2 should also add up to 1. If we take the sum of the label distribution of the carbons of citrate and add the amount of CO 2 we should end up with f P C + f P DC = 1. 
We can repeat this for [2,5- 
Now we can again calculate the total amount of CO 2 produced during the experiment by summing over n:
=2
(1 − c) c
So again the CO 2 production is equal to the sum of carbon labeling at citrate C5 and C6 times the factor 
So the total of 13 C label entering the Krebs cycle is equal to the total 13 C label we find after the experiment in citrate (extracellular or in the incubation medium) and in CO 2 .
PDC versus PC contribution to citrate
13 C-labeling
The equations we found for the 13 C distribution can also easily be split in separate contributions of the PC and PDC route for both the [ 
And for [2,5-13 C 2 ]glucose or [2-13 C]pyruvate we can do the same and end up with the following equations:
Overestimation of secretion
If a part of the molecules are extracted from the Krebs cycle for other metabolic processes, the fraction of molecules remaining in the cycle will be smaller than (1 − c). Let's define a 'leakage factor' 1 − d which includes both the molecules lost to citrate secretion and to other metabolic processes involving for example aspartate and glutamate. So d ≥ c or 1 − d ≤ 1 − c. Now we can recalculate the equations derived earlier, first for [1,6-13 C 2 ]glucose:
For [2,5-13 C 2 ]glucose or [2-13 C]pyruvate we can do the same:
The resulting equations are similar to the equations obtained earlier, but c is replaced by d everywhere and then all equations are multiplied by Calculation of secretion probability c and PC fraction f P C
Experimental ratios
Looking at the equations obtained in sections "Providing [2,5- Table 2 ) we can define experimental ratios of 13 C citrate integrals which can be easily obtained from 13 C MR spectra. Since citrate C2 and C4 on one hand and C1 and C5 on the other are chemically equivalent, we only have to consider ratios of C1/5, C2/4, C3 and C6. We suggest the following experimental ratios of fitted 13 C citrate integrals to be used because they contain the largest integrals for most of the values of c: R 1 for the [ 
If for example c = 0.3 and f P C = 0.2, than R 1 would be R 1 ≈ 0.7. This equation can also be rewritten as an expression for f P DC as a function of c and R 1 : 
In which we inserted the equations for f P DC derived above. If for example c = 0.3 and f P C = 0.2, than R 2 would be R 1 ≈ 3.6. This can be simplified to solve for c by rewriting this into a cubic equation:
After substituting experimentally found values for R 1 and R 2 in this cubic equations, we can solve for c. We can do this for the example values for R 1 and R 2 (for c = 0.3 and f P C = 0.2).
1.3c 3 − 2.7c 2 − 14.3c + 4.5 = 0 (48)
Solving the cubic equations gives us c = 0.3 again.
Fraction f P C vs f
P DC
Now, using the expression we derived earlier we can calculate fraction f P DC (and at the same time f P C ):
Probabily most of the 13 C labels do enter the Krebs cycle via the PDC route and a smaller fraction of the 13 C labels flow into the Krebs cycle of the anaplerotic pathway via pyruvate carboxylase.
Using the values for c and f P C we can calculate the total integrals of the citrate and carbon dioxide carbons according to our model (Figure 8 and 9 ). Looking at the predicted 13 C integrals for the different citrate carbons assuming c = 0.3 and f P C = 0.2, we can see that indeed C2/4 and C3 in the [1,6-13 C 2 ]glucose or [3-13 C]pyruvate experiment is the best choice taking into account SNR, but for the [2,5-13 C 2 ]glucose or [2-13 C]pyruvate experiment the C 1/5 and C 6 signals would have been best to evaluate. However, often the peak of citrate C 6 overlaps with another peak in the 13 C spectrum (e.g. pyroglutamate), making C 3 the best choice.
Average number of Krebs cycle turns
Using equation 4 derived in section "Average number of completed Krebs cycle turns before citrate secretion" the average number of Krebs cycle turns that are completed before secretion of citrate can be calculated:
Pyruvate carboxylase fraction dependence on secretion probability
In section "Fraction f P C vs f P DC " an expression was derived for fraction f P DC (and for f P C using f P C = 1 − f P DC ) depending on c and R 1 . We can derive a similar equation for f P C only depending on c and R 2 .
Using this equation we can plot c versus f P C for different values of R 1 and R 2 (Figure 10 ).; 
Error propagation
The experimental ratios found in the 13 C experiments of course are subject to error due to SNR limitations of the spectra and this has it's effect on the values for c and f P C that we calculated. Assuming a standard deviation of 1%, 2% or 5% of the largest integral in the ratios for all components in the ratio (in a way similar to relative noise levels of 1%, 2% and 5%) and calculate the error propagation and what this would mean for the assumed values of c = 0.3 and f P C = 0.2 we were able to define error bounds for c and f P C (Figure 11 ). A large spread in possible values for c is seen at increasing error, while a more moderate spread is observed in values for f P C .
Effect of efflux of other metabolites
Secretion probability with efflux of other metabolites
In the previous sections we neglected the contributions of other metabolic pathways (both cataplerotic and anaplerotic) to the Krebs cycle carbon pool. We introduced a 'leakage term' in section "Overestimation of secretion" covering all cataplerotic and anaplerotic contributions to the Krebs cycle. However, using R 1 and R 2 and the equations in section "Overestimation of secretion" we can only calculate the total fraction of molecules extracted from the Krebs cycle, d and not separate the citrate secretion from the other processes. Still we can assume c ≤ d. Calculating d using R 1 :
We can now again rewrite the expression to obtain f P DC as a function of d and R 1 :
From the [2,5-13 C 2 ]glucose or [2-13 C]pyruvate experiments we can calculate ratio R 2 :
Substituting the experimentally found values for R 1 and R 2 we can now solve for d Figure 10 : Fraction pyruvate carboxylase f P C versus secretion probability c with lines representing different values for R 1 and R 2 plotted. This means that the real secretion probability for citrate c should be smaller or equal to the value found for d.
Fraction f P C vs f P DC with efflux of other metabolites
Now, using the expression we derived earlier we can calculate fraction f P DC (and at the same time f P C ): So, still most of the 13 C labels do enter the Krebs cycle via the f P DC route. Only a small part of the 13 C labels flow into the Krebs cycle via the anaplerotic pathway via pyruvate carboxylase. The fact that we take leakage into account fortunately does not affect the values of f P C or f P DC .
Average number of Krebs cycle turns with efflux of other metabolites
Calculating the average number of completed cycle turns before secretion of citrate when leakage is involved, can be calculated in a similar way for d as for c.
Probability c versus d
It is not possible to distinguish c and d from each other in the experiments we described, but we do know that the secretion probability c has to be smaller than d if there is carbon flowing out of the Krebs cycle somewhere, so we can say that less than the calculated fraction d of citrate molecules are secreted every cycle turn. The average number of completed cycle turns before secretion of citrate, in the situation that there are no other processes involved, would be even larger. 
Discussion & Conclusions
In this paper we derived a probabilistic model describing the production of citrate in the mitochondria of prostatic epithelial cells and secretion into the luminal space or incubation medium, employing 13 C labeling of secreted citrate as read-out. We were able to calculate the secretion probability for citrate and calculate the contribution of pyruvate dehydrogenase complex (PDC) versus the anaplerotic pyruvate carboxylase (PC) pathway in supplying the Krebs cycle with carbons from pyruvate. We suggest two simple ratios of 13 C NMR signal integrals that can be obtained after supplementation with 13 C labeled glucose or pyruvate to prostate tissue in vivo or cell lines in vitro. This measure is shown to be independent of 13 C-enrichment of the administered supplements. Since the total NMR integrals of the citrate carbons are measured, the model is independent of 13 C J-coupling patterns, making this method more robust if SNR is low. It can be adjusted for use with other 13 C labeled supplements, especially if those are feeding the acetyl-CoA pool. Next to this an estimation of pyruvate carboxylase (PC) contribution and pyruvate dehydrogenase complex (PDC) contribution of carbon entering the Krebs cycle is provided.
We assumed the 13 C pyruvate pool to be large compared to the Krebs cycle 13 C pool, which results in an average constant flow of 13 C labels flowing into the Krebs cycle over time. Another assumption made in deriving this model is the constant secretion probability of citrate over time. If the tissue or cells are provided with a constant flow of 13 C label for a long period of time, we assume that the epithelial cells are in a steady state with respect to citrate production and general metabolism on average during this period.
After citrate diverges from the Krebs cycle and is transported to the cytosol it can be used in de novo lipid sythesis and other metabolism. Assuming lipid synthesis and secretion of citrate by the transporters out of the cells is constant over time this doesn't influence the 13 C labeling pattern found for citrate in the extracellular fluid or incubation medium since an equal fraction of all citrate present in the cytosol will be lost to lipid synthesis or other metabolism independent of the 13 C labeling of the citrate. Only if the 13 C labels subsequently end up in the Krebs cycle again this could influence the final outcome of the experiments, but we assume this to be negligible.
Apart from secretion of citrate, we assumed no other efflux of metabolites during each cycle turn, which makes the secretion probability described earlier an upper limit for citrate secretion. The secretion probability calculated from experimental values using this model reflects on the total fraction of molecules diverging from the Krebs cycle during one cycle turn, not only citrate. The efflux of other metabolites is shown in section "Overestimation of secretion" to not have an effect on the value of f P C or f P DC but it does result in an overestimation of secretion probability c. Efflux from the Krebs cycle pool can be due to for example conversion of α-ketoglutarate into glutamate by glutamate dehydrogenase, pyruvate production from oxaloacetate via PEPCK and aspartate transaminase activity. The latter is part of the malate-aspartate shuttle and catalyzes the conversion of α-ketoglutarate into glutamate and of oxaloacetate into aspartate, and contributes to the efflux of metabolites from the Krebs cycle for production of amino acids and proteins. Multiple metabolic flux modeling studies have calculated total Krebs cycle fluxes and net influx and efflux from the Krebs cycle. In some cases exchange fluxes were calculated in addition to net fluxes. Especially interesting is the high exchange flux associated with the exchange between α-ketoglutarate and glutamate, comparable or even exceeding total Krebs cycle fluxes in vivo in tissues like heart 25,27 and brain 24, [28] [29] [30] . But also in vitro in metastatic cell lines like melanoma 17, 18 , hepatocyte and hepatoma 23 and glioma 19 cells. Depending on the size of the unlabeled glutamate pool this can result in a fast isotopical dilution of the α-ketoglutarate pool, resulting in loss of 13 C labeled carbon skeletons. This and the loss of 13 C-labeled Krebs cycle metabolites to other parts of metabolism accounts for the efflux of metabolites from the Krebs cycle. Until now no literature values for similar exchange fluxes are available for prostate tissues or cell systems. Future efforts can be made to extend the model with an estimation of loss of 13 C labeled carbon skeletons to glutamate using intracellular glutamate pool size and (relative) exchange fluxes. Other abundant metabolites diverging from the Krebs cycle should be identified as well to better estimate the fraction of citrate secretion to the total loss of carbon skeletons from the Krebs cycle. Including efflux of metabolites during a Krebs cycle turn would decrease the estimated secretion probability for citrate. The average number of completed Krebs cycle turns before secretion of citrate that is calculated depends on the total efflux of metabolites from the cycle, not only on the secretion of citrate.
The high labeling efficiency of citrate using the 13 C substrates described here make these substrates ideal candidates for studying the unique secretion of citrate by prostate tissue. Still, extending this model to other 13 C labeled substrates or other isotopes like 14 C or 2 H could be of interest in future studies.
We propose in this model an index for citrate production and secretion in prostatic tissue versus Krebs cycle activity. A change in this index could indicate a shift in metabolism and could be used to probe therapy effectiveness. For this it would be necessary to first measure a baseline index in healthy prostate tissue by measuring citrate secreted by healthy epithelial tissue in vivo and secondly determine how much the index changes upon malignancy or treatment.
Appendix
Average number of Krebs cycle turns for a 13 
C label
The average number of Krebs cycle turns a 13 C carbon completes before ending up in either citrate or carbon dioxide depends on the carbon position it starts out from at n = 0. For a 13 C carbon starting at citrate C2 or C3 the fraction of 13 C carbon ending up in citrate or carbon dioxide during Krebs cycle turn n is: Again we can calculate the average number of cycle turns a 13 C carbon starting at citrate C1 or C4 completes before secretion in citrate or ending up in carbon dioxide. 
Depending on the 13 C substrate is used the 13 C carbons in citrate start at different positions at n = 0. For [ 
= f P C (3 + c)(1 − c)
This is plotted for f P C = 0.2 in Figure 12 .
Figure 12: Average number of Krebs cycle turns a 13 C carbon completes before being secreted in citrate or being lost into carbon dioxide versus secretion probability c. The fraction pyruvate carboxylase is set to f P C = 0.2 and the values at c = 0.3 are indicated with squares.
